FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2756229621> ?p ?o ?g. }

• W2756229621 abstract "BackgroundThe appearance of tumor necrosis factor-alpha (TNFalpha) inhibitors dramatically changed the prognosis of rheumatoid arthritis. Certolizumab pegol (CZP) is a human Fab fragment of anti-TNFalpha monoclonal antibody which is approved for the treatment of rheumatoid arthritis. We performed a systematic review and meta-analysis, with Cochrane methodology, of the effects of CZP in rheumatoid arthritis.ObjectivesTo assess the clinical benefits and harms of CZP in patients with rheumatoid arthritis.MethodsWe performed a search of electronic database (Cochrane Database, MEDLINE, EMBASE, Web of Knowledge and clinicaltrials.gov) until 26th September 2016. We searched for randomized controlled trials of CZP in rheumatoid arthritis compared to any other agent including placebo.Results14 trials were included for the meta-analysis, 12 (5422 patients) in the pooled analysis for benefits and 14 (5499 patients) in the pooled analysis for safety. The overall possibility of bias seemed to be low but the quality of the evidence was low due to the risk of attrition bias.With the approved dose - CZP 200 mg subcutaneous every other week with the first three doses of 400 mg - CZP showed statistically significant improvements at 24 weeks compared to placebo in: ACR50 absolute improvement 27% (95% CI 20% to 33%), RR 3.8 (95% CI 2.42 to 5.95) and NNT=4 (95% CI 3 to 8); DAS28 <2.6 - original definition of remission - with RR 3.79 (95% CI 1.90 to 7.56); HAQ with -12% absolute improvement (95% CI -9% to -14%); and erosion score with -0.29% (95% CI -0.42% to -0.17%). There are also data available at 12 weeks with RR of 1.99 (95% CI 1.44 to 2.76) of achieving DAS28<2.6 with CZP 200 mg dose. The proportion of patients achieving DAS28<2.6 was still higher with CZP at 52 weeks with RR of 1.83 (95% CI 1.53 to 2.18).Serious adverse events were more frequent for CZP 200 mg dose with a RR of 1.47 (95% CI 1.13 to 1.91) and NNH of 32. There have been eight adverse events leading to death in CZP 200 mg group versus two in the control group (not statistically significant) and 10 patients developing tuberculosis versus two in the control group (not statistically significant).ConclusionsThere is low level evidence from randomized controlled trials that CZP as monotherapy or combined with methotrexate improved ACR50, DAS28, HAQ and joint damaged on x-ray. Adverse events were more frequent with active treatment." @default.
• W2756229621 created "2017-09-25" @default.
• W2756229621 creator A5025085644 @default.
• W2756229621 creator A5028984464 @default.
• W2756229621 creator A5043005051 @default.
• W2756229621 creator A5054502003 @default.
• W2756229621 creator A5066037713 @default.
• W2756229621 creator A5087068978 @default.
• W2756229621 date "2017-06-01" @default.
• W2756229621 modified "2023-10-18" @default.
• W2756229621 title "FRI0199 Systematic review and meta-analysis on certolizumab pegol for rheumatoid arthritis in adults" @default.
• W2756229621 doi "https://doi.org/10.1136/annrheumdis-2017-eular.6433" @default.
• W2756229621 hasPublicationYear "2017" @default.
• W2756229621 type Work @default.
• W2756229621 sameAs 2756229621 @default.
• W2756229621 citedByCount "1" @default.
• W2756229621 countsByYear W27562296212022 @default.
• W2756229621 crossrefType "proceedings-article" @default.
• W2756229621 hasAuthorship W2756229621A5025085644 @default.
• W2756229621 hasAuthorship W2756229621A5028984464 @default.
• W2756229621 hasAuthorship W2756229621A5043005051 @default.
• W2756229621 hasAuthorship W2756229621A5054502003 @default.
• W2756229621 hasAuthorship W2756229621A5066037713 @default.
• W2756229621 hasAuthorship W2756229621A5087068978 @default.
• W2756229621 hasBestOaLocation W27562296211 @default.
• W2756229621 hasConcept C126322002 @default.
• W2756229621 hasConcept C2776215756 @default.
• W2756229621 hasConcept C2777077863 @default.
• W2756229621 hasConcept C2777575956 @default.
• W2756229621 hasConcept C2780132546 @default.
• W2756229621 hasConcept C71924100 @default.
• W2756229621 hasConcept C95190672 @default.
• W2756229621 hasConceptScore W2756229621C126322002 @default.
• W2756229621 hasConceptScore W2756229621C2776215756 @default.
• W2756229621 hasConceptScore W2756229621C2777077863 @default.
• W2756229621 hasConceptScore W2756229621C2777575956 @default.
• W2756229621 hasConceptScore W2756229621C2780132546 @default.
• W2756229621 hasConceptScore W2756229621C71924100 @default.
• W2756229621 hasConceptScore W2756229621C95190672 @default.
• W2756229621 hasLocation W27562296211 @default.
• W2756229621 hasLocation W27562296212 @default.
• W2756229621 hasOpenAccess W2756229621 @default.
• W2756229621 hasPrimaryLocation W27562296211 @default.
• W2756229621 hasRelatedWork W2029132123 @default.
• W2756229621 hasRelatedWork W2056056959 @default.
• W2756229621 hasRelatedWork W2156283049 @default.
• W2756229621 hasRelatedWork W2316954211 @default.
• W2756229621 hasRelatedWork W2317539666 @default.
• W2756229621 hasRelatedWork W2327246029 @default.
• W2756229621 hasRelatedWork W2427075784 @default.
• W2756229621 hasRelatedWork W2761967325 @default.
• W2756229621 hasRelatedWork W4245782456 @default.
• W2756229621 hasRelatedWork W4308319343 @default.
• W2756229621 isParatext "false" @default.
• W2756229621 isRetracted "false" @default.
• W2756229621 magId "2756229621" @default.
• W2756229621 workType "article" @default.